Develops potential medicines for people with epilepsy, immune diseases, and neuromuscular and metabolic conditions.
10-K for FY2025, filed Mar 2, 2026
10-Q for Q3 FY2026, filed Oct 29, 2026
−$129.3MView ↗
8-K, filed Oct 15, 2026
Under the License Agreement, Ono will pay the Company a one-time, non-creditable and non-refundable upfront payment of $80 million upon…View ↗
8-K, filed Aug 26, 2026
Under the License Agreement, SKBP will pay BBIL a non-creditable and non-refundable upfront fee of $400 million, consisting of $350 million…View ↗
Narrower clinical focus
The older report described a broad pipeline centered on neurological and neuropsychiatric diseases, with programs spanning multiple platforms. The latest report describes a narrower focus on epilepsy, protein-degrader treatments for immune diseases, and treatments for neuromuscular and metabolic diseases.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 2, 2026We are a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing…View ↗
In the fourth quarter of 2025, we initiated strategic portfolio and cost-optimization measures to prioritize three key, late-stage…View ↗
Competes with Glenmark
10-K for FY2025, filed Mar 2, 2026Since the Nobel Prize-winning discovery of the capsaicin receptor TRPV1 in 1997, members of the TRP cation channel family have been elusive…View ↗
Loading...